• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

危重症患者的药物代谢有哪些变化——III?基础疾病对咪达唑仑代谢的影响。

What changes drug metabolism in critically ill patients--III? Effect of pre-existing disease on the metabolism of midazolam.

作者信息

Park G R, Miller E

机构信息

Anaesthesia Drug Metabolism Laboratory, Addenbrooke's Hospital, Cambridge.

出版信息

Anaesthesia. 1996 May;51(5):431-4. doi: 10.1111/j.1365-2044.1996.tb07785.x.

DOI:10.1111/j.1365-2044.1996.tb07785.x
PMID:8694153
Abstract

Liver samples were obtained at hepatectomy from patients with end stage alcoholic liver disease (n = 5), primary biliary cirrhosis (n = 5) and chronic rejection needing retransplantation (n = 5). Normal liver material was also obtained from five organ donors. From these samples microsomes were made containing cytochrome P450 3A. The amount of this enzyme was measured by Western immunoblotting and its function assessed by measuring the rate of production of two metabolites of midazolam, 1-hydroxy midazolam and 4-hydroxy midazolam. There was a wide range in all groups for both the expression and function of this enzyme. Liver tissue affected by cirrhotic disease showed greater preservation of enzyme function than that affected by hepatocellular disease. There was a good correlation between the expression of the enzyme and production of the 1-hydroxy metabolite, but a poor correlation between production of the 4-hydroxy metabolite and expression. This poor correlation may reflect the failure to measure the specific enzyme responsible for producing 4-hydroxy midazolam.

摘要

在肝切除术中从患有终末期酒精性肝病(n = 5)、原发性胆汁性肝硬化(n = 5)和需要再次移植的慢性排斥反应(n = 5)的患者身上获取肝脏样本。还从五名器官供体获取了正常肝脏组织。从这些样本中制备了含有细胞色素P450 3A的微粒体。通过蛋白质免疫印迹法测量该酶的量,并通过测量咪达唑仑的两种代谢产物1-羟基咪达唑仑和4-羟基咪达唑仑的生成速率来评估其功能。在所有组中,该酶的表达和功能都有很大差异。受肝硬化疾病影响的肝组织比受肝细胞疾病影响的肝组织显示出更好的酶功能保留。该酶的表达与1-羟基代谢产物的生成之间存在良好的相关性,但4-羟基代谢产物的生成与表达之间的相关性较差。这种较差的相关性可能反映了未能测量负责生成4-羟基咪达唑仑的特定酶。

相似文献

1
What changes drug metabolism in critically ill patients--III? Effect of pre-existing disease on the metabolism of midazolam.危重症患者的药物代谢有哪些变化——III?基础疾病对咪达唑仑代谢的影响。
Anaesthesia. 1996 May;51(5):431-4. doi: 10.1111/j.1365-2044.1996.tb07785.x.
2
What changes drug metabolism in critically ill patients?--II Serum inhibits the metabolism of midazolam in human microsomes.
Anaesthesia. 1996 Jan;51(1):11-5. doi: 10.1111/j.1365-2044.1996.tb07646.x.
3
Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.人细胞色素P450 3A(CYP3A)亚家族成员对咪达唑仑的区域选择性生物转化。
Biochem Pharmacol. 1994 Apr 29;47(9):1643-53. doi: 10.1016/0006-2952(94)90543-6.
4
Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice.肝硬化患者中咪达唑仑的肠道首过代谢——葡萄柚汁的影响。
Br J Clin Pharmacol. 2002 Aug;54(2):120-4. doi: 10.1046/j.1365-2125.2002.01615.x.
5
Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.咪达唑仑作为人细胞色素P450 3A探针的应用:I. 肝移植患者的体外-体内相关性
J Pharmacol Exp Ther. 1994 Oct;271(1):549-56.
6
Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.咪达唑仑和三唑仑在小鼠和人肝微粒体中的生物转化:CYP3A和CYP2C同工型的相对贡献。
J Pharmacol Exp Ther. 2000 Feb;292(2):618-28.
7
Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.大鼠、人以及 cDNA 表达的人细胞色素 P450 微粒体中细胞色素 P4503A 活性的抑制作用及动力学
Drug Metab Dispos. 1996 Sep;24(9):940-7.
8
Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.咪达唑仑作为人细胞色素P450 3A探针的应用:II. 肝移植后个体间和个体内肝脏CYP3A变异性的特征
J Pharmacol Exp Ther. 1994 Oct;271(1):557-66.
9
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.咪达唑仑的口服首过消除涉及胃肠道和肝脏中细胞色素P450 3A(CYP3A)介导的代谢。
Clin Pharmacol Ther. 1996 May;59(5):491-502. doi: 10.1016/S0009-9236(96)90177-0.
10
Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes.人细胞色素P450酶对瓦诺西汀(1-[2-[双(4-氟苯基)甲氧基]乙基]-4-(3-苯基丙基)哌嗪)的代谢作用
Drug Metab Dispos. 2001 Sep;29(9):1216-20.

引用本文的文献

1
Monitoring of sedation depth in intensive care unit by therapeutic drug monitoring? A prospective observation study of medical intensive care patients.通过治疗药物监测来监测重症监护病房的镇静深度?一项针对医学重症监护患者的前瞻性观察研究。
J Intensive Care. 2018 Sep 14;6:62. doi: 10.1186/s40560-018-0331-7. eCollection 2018.
2
Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.重症监护病房中危重症或创伤成年患者的镇静:观念的转变。
Drugs. 2012 Oct 1;72(14):1881-916. doi: 10.2165/11636220-000000000-00000.
3
Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.
治疗脓毒症和脓毒性休克患者时的药代动力学和药效学考量
Clin Pharmacokinet. 2002;41(14):1135-51. doi: 10.2165/00003088-200241140-00002.
4
Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers.健康志愿者中咪达唑仑和利多卡因药代动力学与MEGX形成之间的相关性。
Br J Clin Pharmacol. 2002 Feb;53(2):133-9. doi: 10.1046/j.0306-5251.2001.01182.x.
5
Pain management in the critically ill child.危重症患儿的疼痛管理
Indian J Pediatr. 2001 Aug;68(8):749-69. doi: 10.1007/BF02752416.
6
Drugs used in physician-assisted death.用于医生协助死亡的药物。
Drugs Aging. 1999 Nov;15(5):335-40. doi: 10.2165/00002512-199915050-00001.
7
Pharmacokinetics of drugs used in critically ill adults.危重症成年患者使用药物的药代动力学
Clin Pharmacokinet. 1998 Jan;34(1):25-56. doi: 10.2165/00003088-199834010-00002.